ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Liver, Gallbladder, and Biliary Tract Cancers

Liver, Gallbladder, and Biliary Tract Cancers

Adjuvant chemotherapy for biliary tract cancer using GEMOX (gemcitabine/oxaliplatin) was feasible, but did not result in an improved recurrence-free survival or quality of life compared with surveillance in the phase III PRODIGE 12-ACCORD 18 trial.

Use of stereotactic body radiation therapy (SBRT) was equally effective as transarterial chemoembolization (TACE) as a method of bridge to transplant among patients with hepatocellular carcinoma.

A new study has identified several trends by race and ethnicity among patients with hepatocellular carcinoma (HCC) in the United States.

Regular use of aspirin may reduce the risk of developing cholangiocarcinoma, according to the results of a new study.

Researchers from the National Cancer Institute are predicting that the rate of hepatocellular carcinoma (HCC) in the United States will likely decrease by the year 2030.

US-born Hispanics are more likely to get hepatocellular carcinoma and to die from chronic liver disease compared with their foreign-born counterparts.

Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.

Pages

Subscribe to Liver, Gallbladder, and Biliary Tract Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.